Cargando…

Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study

BACKGROUND: Artemisinin-based combination therapy (ACT), the treatment of choice for uncomplicated falciparum malaria, is unaffordable and generally inaccessible in the private sector, the first port of call for most malaria treatment across rural Africa. Between August 2007 and May 2010, the Uganda...

Descripción completa

Detalles Bibliográficos
Autores principales: Talisuna, Ambrose O, Daumerie, Penny Grewal, Balyeku, Andrew, Egan, Timothy, Piot, Bram, Coghlan, Renia, Lugand, Maud, Bwire, Godfrey, Rwakimari, John Bosco, Ndyomugyenyi, Richard, Kato, Fred, Byangire, Maria, Kagwa, Paul, Sebisubi, Fred, Nahamya, David, Bonabana, Angela, Mpanga-Mukasa, Susan, Buyungo, Peter, Lukwago, Julius, Batte, Allan, Nakanwagi, Grace, Tibenderana, James, Nayer, Kinny, Reddy, Kishore, Dokwal, Nilesh, Rugumambaju, Sylvester, Kidde, Saul, Banerji, Jaya, Jagoe, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523984/
https://www.ncbi.nlm.nih.gov/pubmed/23107021
http://dx.doi.org/10.1186/1475-2875-11-356
_version_ 1782253254209437696
author Talisuna, Ambrose O
Daumerie, Penny Grewal
Balyeku, Andrew
Egan, Timothy
Piot, Bram
Coghlan, Renia
Lugand, Maud
Bwire, Godfrey
Rwakimari, John Bosco
Ndyomugyenyi, Richard
Kato, Fred
Byangire, Maria
Kagwa, Paul
Sebisubi, Fred
Nahamya, David
Bonabana, Angela
Mpanga-Mukasa, Susan
Buyungo, Peter
Lukwago, Julius
Batte, Allan
Nakanwagi, Grace
Tibenderana, James
Nayer, Kinny
Reddy, Kishore
Dokwal, Nilesh
Rugumambaju, Sylvester
Kidde, Saul
Banerji, Jaya
Jagoe, George
author_facet Talisuna, Ambrose O
Daumerie, Penny Grewal
Balyeku, Andrew
Egan, Timothy
Piot, Bram
Coghlan, Renia
Lugand, Maud
Bwire, Godfrey
Rwakimari, John Bosco
Ndyomugyenyi, Richard
Kato, Fred
Byangire, Maria
Kagwa, Paul
Sebisubi, Fred
Nahamya, David
Bonabana, Angela
Mpanga-Mukasa, Susan
Buyungo, Peter
Lukwago, Julius
Batte, Allan
Nakanwagi, Grace
Tibenderana, James
Nayer, Kinny
Reddy, Kishore
Dokwal, Nilesh
Rugumambaju, Sylvester
Kidde, Saul
Banerji, Jaya
Jagoe, George
author_sort Talisuna, Ambrose O
collection PubMed
description BACKGROUND: Artemisinin-based combination therapy (ACT), the treatment of choice for uncomplicated falciparum malaria, is unaffordable and generally inaccessible in the private sector, the first port of call for most malaria treatment across rural Africa. Between August 2007 and May 2010, the Uganda Ministry of Health and the Medicines for Malaria Venture conducted the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study to test whether access to ACT in the private sector could be improved through the provision of a high level supply chain subsidy. METHODS: Four intervention districts were purposefully selected to receive branded subsidized medicines - “ACT with a leaf”, while the fifth district acted as the control. Baseline and evaluation outlet exit surveys and retail audits were conducted at licensed and unlicensed drug outlets in the intervention and control districts. A survey-adjusted, multivariate logistic regression model was used to analyse the intervention’s impact on: ACT uptake and price; purchase of ACT within 24 hours of symptom onset; ACT availability and displacement of sub-optimal anti-malarial. RESULTS: At baseline, ACT accounted for less than 1% of anti-malarials purchased from licensed drug shops for children less than five years old. However, at evaluation, “ACT with a leaf” accounted for 69% of anti-malarial purchased in the interventions districts. Purchase of ACT within 24 hours of symptom onset for children under five years rose from 0.8% at baseline to 26.2% (95% CI: 23.2-29.2%) at evaluation in the intervention districts. In the control district, it rose modestly from 1.8% to 5.6% (95% CI: 4.0-7.3%). The odds of purchasing ACT within 24 hours in the intervention districts compared to the control was 0.46 (95% CI: 0.08-2.68, p=0.4) at baseline and significant increased to 6.11 (95% CI: 4.32-8.62, p<0.0001) at evaluation. Children less than five years of age had “ACT with a leaf” purchased for them more often than those aged above five years. There was no evidence of price gouging. CONCLUSIONS: These data demonstrate that a supply-side subsidy and an intensive communications campaign significantly increased the uptake and use of ACT in the private sector in Uganda.
format Online
Article
Text
id pubmed-3523984
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35239842012-12-18 Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study Talisuna, Ambrose O Daumerie, Penny Grewal Balyeku, Andrew Egan, Timothy Piot, Bram Coghlan, Renia Lugand, Maud Bwire, Godfrey Rwakimari, John Bosco Ndyomugyenyi, Richard Kato, Fred Byangire, Maria Kagwa, Paul Sebisubi, Fred Nahamya, David Bonabana, Angela Mpanga-Mukasa, Susan Buyungo, Peter Lukwago, Julius Batte, Allan Nakanwagi, Grace Tibenderana, James Nayer, Kinny Reddy, Kishore Dokwal, Nilesh Rugumambaju, Sylvester Kidde, Saul Banerji, Jaya Jagoe, George Malar J Research BACKGROUND: Artemisinin-based combination therapy (ACT), the treatment of choice for uncomplicated falciparum malaria, is unaffordable and generally inaccessible in the private sector, the first port of call for most malaria treatment across rural Africa. Between August 2007 and May 2010, the Uganda Ministry of Health and the Medicines for Malaria Venture conducted the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study to test whether access to ACT in the private sector could be improved through the provision of a high level supply chain subsidy. METHODS: Four intervention districts were purposefully selected to receive branded subsidized medicines - “ACT with a leaf”, while the fifth district acted as the control. Baseline and evaluation outlet exit surveys and retail audits were conducted at licensed and unlicensed drug outlets in the intervention and control districts. A survey-adjusted, multivariate logistic regression model was used to analyse the intervention’s impact on: ACT uptake and price; purchase of ACT within 24 hours of symptom onset; ACT availability and displacement of sub-optimal anti-malarial. RESULTS: At baseline, ACT accounted for less than 1% of anti-malarials purchased from licensed drug shops for children less than five years old. However, at evaluation, “ACT with a leaf” accounted for 69% of anti-malarial purchased in the interventions districts. Purchase of ACT within 24 hours of symptom onset for children under five years rose from 0.8% at baseline to 26.2% (95% CI: 23.2-29.2%) at evaluation in the intervention districts. In the control district, it rose modestly from 1.8% to 5.6% (95% CI: 4.0-7.3%). The odds of purchasing ACT within 24 hours in the intervention districts compared to the control was 0.46 (95% CI: 0.08-2.68, p=0.4) at baseline and significant increased to 6.11 (95% CI: 4.32-8.62, p<0.0001) at evaluation. Children less than five years of age had “ACT with a leaf” purchased for them more often than those aged above five years. There was no evidence of price gouging. CONCLUSIONS: These data demonstrate that a supply-side subsidy and an intensive communications campaign significantly increased the uptake and use of ACT in the private sector in Uganda. BioMed Central 2012-10-29 /pmc/articles/PMC3523984/ /pubmed/23107021 http://dx.doi.org/10.1186/1475-2875-11-356 Text en Copyright ©2012 Talisuna et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Talisuna, Ambrose O
Daumerie, Penny Grewal
Balyeku, Andrew
Egan, Timothy
Piot, Bram
Coghlan, Renia
Lugand, Maud
Bwire, Godfrey
Rwakimari, John Bosco
Ndyomugyenyi, Richard
Kato, Fred
Byangire, Maria
Kagwa, Paul
Sebisubi, Fred
Nahamya, David
Bonabana, Angela
Mpanga-Mukasa, Susan
Buyungo, Peter
Lukwago, Julius
Batte, Allan
Nakanwagi, Grace
Tibenderana, James
Nayer, Kinny
Reddy, Kishore
Dokwal, Nilesh
Rugumambaju, Sylvester
Kidde, Saul
Banerji, Jaya
Jagoe, George
Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study
title Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study
title_full Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study
title_fullStr Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study
title_full_unstemmed Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study
title_short Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study
title_sort closing the access barrier for effective anti-malarials in the private sector in rural uganda: consortium for act private sector subsidy (capss) pilot study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523984/
https://www.ncbi.nlm.nih.gov/pubmed/23107021
http://dx.doi.org/10.1186/1475-2875-11-356
work_keys_str_mv AT talisunaambroseo closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT daumeriepennygrewal closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT balyekuandrew closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT egantimothy closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT piotbram closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT coghlanrenia closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT lugandmaud closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT bwiregodfrey closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT rwakimarijohnbosco closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT ndyomugyenyirichard closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT katofred closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT byangiremaria closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT kagwapaul closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT sebisubifred closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT nahamyadavid closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT bonabanaangela closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT mpangamukasasusan closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT buyungopeter closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT lukwagojulius closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT batteallan closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT nakanwagigrace closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT tibenderanajames closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT nayerkinny closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT reddykishore closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT dokwalnilesh closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT rugumambajusylvester closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT kiddesaul closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT banerjijaya closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy
AT jagoegeorge closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy